Leuprorelin

Source: Wikipedia, the free encyclopedia.

Leuprorelin
Clinical data
Trade namesLupron, Eligard, Lucrin, Lupaneta, others
Other namesleuprolide, leuprolidine, A-43818, Abbott-43818, DC-2-269, TAP-144
AHFS/Drugs.comMonograph
MedlinePlusa685040
License data
Pregnancy
category
  • AU: D
GnRH agonist; Antigonadotropin
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life3 hours
ExcretionKidney
Identifiers
  • N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-
    [2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxo-pentan-2-
    yl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-
    butyl]carbamoyl]-2-(4-hydroxyphenyl)ethyl]
    carbamoyl]-2-hydroxy-ethyl]carbamoyl]-2-(1H-indol-3-
    yl)ethyl]carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-5-oxo-
    pyrrolidine-2-carboxamide
JSmol)
  • CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]c4c3cccc4)NC(=O)[C@H](Cc5c[nH]cn5)NC(=O)[C@@H]6CCC(=O)N6
  • InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1 ☒N
  • Key:GFIJNRVAKGFPGQ-LIJARHBVSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Leuprorelin, also known as leuprolide, is a manufactured version of a

under the skin.[10]

Leuprorelin is in the

allergic reactions, and problems with the pituitary gland.[10] Use during pregnancy may harm foetal development.[10]

Leuprorelin was patented in 1973 and approved for medical use in the United States in 1985.[10][12] It is on the World Health Organization's List of Essential Medicines.[11] It is sold under the brand name Lupron among others.[10]

Medical use

Leuprorelin may be used in the treatment of hormone-responsive

uterine fibroids
.

It may be used for precocious puberty in both males and females,[14] and to prevent premature ovulation in cycles of controlled ovarian stimulation for in vitro fertilization (IVF). This use is controversial since the Lupron label advises against using the drug when one is considering pregnancy, due to a risk of birth defects.[15]

It may be used to reduce the risk of

premature ovarian failure in women receiving cyclophosphamide for chemotherapy.[16]

Along with

Tanner stages 2–3, and then cross-sex hormones treatment at age 16. This use of the drug is off-label, however, not having been approved by the Food and Drug Administration and without data on long-term effects of this use.[needs update][18]

They are also sometimes used as alternatives to antiandrogens like spironolactone and cyproterone acetate for suppressing testosterone production in transgender women.[19][20][21] It also is used for suppressing estrogen production in transgender men.[22]

It is considered a possible treatment for paraphilias.[23] Leuprorelin has been tested as a treatment for reducing sexual urges in pedophiles and other cases of paraphilia.[24][25]

Lupron "Flare"

During the initial phase of luteinizing hormone-releasing hormone (LHRH) agonist therapy, there is a notable phenomenon known as the "flare." This occurs when testosterone levels temporarily surge by approximately 50% within the first 1 to 2 weeks of therapy. This increase is a response to the initial stimulation of luteinizing hormone (LH) by the LHRH agonist, leading to a rise in testosterone levels before they begin to decrease as intended. For individuals receiving LHRH agonists as part of gender-affirming care, this temporary increase in testosterone can be particularly distressing, exacerbating gender dysphoria and discomfort. To manage and mitigate these effects, healthcare providers often prescribe antiandrogens during this phase to help block the unwanted increase in testosterone and alleviate the associated distress.[26]

Side effects

Common side effects of leuprorelin injection include redness/burning/stinging/pain/bruising at the injection site, hot flashes (flushing), increased sweating, night sweats, tiredness, headache, upset stomach, nausea, diarrhea, impotence, testicular shrinkage,[8] constipation, stomach pain, breast swelling or tenderness, acne, joint/muscle aches or pain, trouble sleeping (insomnia), reduced sexual interest, vaginal discomfort/dryness/itching/discharge, vaginal bleeding, swelling of the ankles/feet, increased urination at night, dizziness, breakthrough bleeding in a female child during the first two months of leuprorelin treatment, weakness, chills, clammy skin, skin redness, itching, or scaling, testicle pain, impotence, depression, or memory problems.[27] The rates of gynecomastia with leuprorelin have been found to range from 3 to 16%.[28]

A cohort of women that were prescribed leuprorelin to delay precocious puberty as children has developed osteoporosis and brittle teeth at an unexpected rate; However, the FDA has not established that these conditions were caused by leuprorelin.[29]

Pharmacology

Mechanism of action

Leuprorelin is a

GnRH receptors. GnRH receptor agonists initially increase the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the anterior pituitary and increased serum estradiol and testosterone levels via the hypothalamic–pituitary–gonadal axis (HPG axis). However, normal functioning of this axis requires pulsatile release of GnRH from the hypothalamus. Continuous exposure to an agonist such as leuprorelin for several weeks causes pituitary GnRH receptors to become desensitised and no longer responsive. This desensitisation is the objective of leuprorelin therapy because it ultimately reduces LH and FSH secretion, leading to hypogonadism and a dramatic reduction in estradiol and testosterone levels regardless of sex.[30][31]

Available forms

Leuprorelin is available in the following forms, among others:[32][33][34][35][36]

  • Short-acting daily intramuscular injection (Lupron)[4]
  • Long-acting depot intramuscular injection (Lupron Depot)[8][37][38][39]
  • Long-acting depot subcutaneous injection (Eligard)[5]
  • Long-acting subcutaneous injection (Fensolvi)[6]
  • Long-acting subcutaneous implant (Viadur)[7]
  • Long-acting leuprolide mesylate (Camcevi) for the treatment of advanced prostate cancer.[40]
  • Leuprolide acetate and norethindrone acetate co-packaged pack (Lupaneta Pack)[41][42]

Chemistry

The

pyroglutamyl
).

History

Leuprorelin was discovered and first patented in 1973 and was introduced for medical use in 1985.[43][44] It was initially marketed only for daily injection, but a depot injection formulation was introduced in 1989.[44]

Approvals

  • Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985.[45][4][43][44]
  • Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989.[8]
  • Viadur was approved by the FDA for palliative treatment of advanced prostate cancer on 6 March 2000.[7]
  • Eligard was approved by the FDA for palliative treatment of advanced prostate cancer on 24 January 2002.[5]
  • Fensolvi was approved by the FDA for children with central precocious puberty on 4 May 2020.[6][46]

Society and culture

Legal status

On 24 March 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Camcevi, intended for the treatment of the cancer of the prostate in adult men when the cancer is "hormone-dependent", which means that it responds to treatments that reduce the levels of the hormone testosterone.[47] The applicant for this medicinal product is Accord Healthcare S.L.U.[47] Leuprorelin was approved for medical use in the European Union in May 2022.[9][48]

Names

Leuprorelin is the

INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while leuprorelin acetate is its BANMTooltip British Approved Name and JANTooltip Japanese Accepted Name, leuprolide acetate is its USANTooltip United States Adopted Name and USPTooltip United States Pharmacopeia, leuprorelina is its DCITTooltip Denominazione Comune Italiana, and leuproréline is its DCFTooltip Dénomination Commune Française.[49][50][51][52] It is also known by its developmental code names A-43818, Abbott-43818, DC-2-269, and TAP-144.[49][50][51][52]

Leuprorelin is marketed by Bayer AG under the brand name Viadur,[7] by Tolmar under the brand names Eligard and Fensolvi,[5][6] and by TAP Pharmaceuticals (1985–2008), by Varian Darou Pajooh under the brand name Leupromer and Abbott Laboratories (2008–present) under the brand name Lupron.

Controversy

In October 2001, the US Department of Justice, states attorneys general, and TAP Pharmaceutical Products, a subsidiary of Abbott Laboratories, settled criminal and civil charges against TAP related to federal and state

False Claims Act with claims filed by Douglas Durand, a former TAP vice president of sales, and Joseph Gerstein, a doctor at Tufts University's HMO practice.[54] Durand, Gerstein, and Tufts shared $95 million of the settlement.[54]

There have since been various suits concerning leuprorelin use, none successful.[56][57] They either concern the oversubscription of the drug or undue warning about the side effects. Between 2010 and 2013, the FDA updated the Lupron drug label to include new safety information on the risk of thromboembolism, loss of bone density and convulsions.[58] The FDA then asserted that the benefits of leuprorelin outweigh its risks when used according to its approved labeling. Since 2017, the FDA has been evaluating leuprorelin's connection to pain and discomfort in musculoskeletal and connective tissue.[59]

Research

As of 2006, leuprorelin was under investigation for possible use in the treatment of mild to moderate Alzheimer's disease.[60][needs update]

A

uterine fibroids, but development for these uses was discontinued.[61] The formulation has the tentative brand name Ovarest.[61] As of July 2018, it is in phase II clinical trials for endometriosis.[61][needs update
]

Veterinary use

Leuprorelin is frequently used in ferrets for the treatment of

primary hyperaldosteronism,[62] and one with concurrent diabetes mellitus.[63] It is also used to treat pet parrots with chronic egg laying behavior.[64]

References

  1. ^ ELIGARD (Mundipharma Pty Ltd) Department of Health and Aged Care. Retrieved 30 March 2023
  2. ^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
  3. ^ "Regulatory Decision Summary for Eligard". Drug and Health Products Portal. 21 September 2023. Retrieved 2 April 2024.
  4. ^ a b c "Lupron- leuprolide acetate lupron- leuprolide acetate injection, solution". DailyMed. Archived from the original on 27 May 2021. Retrieved 27 May 2021.
  5. ^ a b c d "Eligard- leuprolide acetate kit". DailyMed. 26 March 2020. Archived from the original on 10 August 2020. Retrieved 20 August 2020.
  6. ^ a b c d "Fensolvi- leuprolide acetate kit". DailyMed. 3 June 2020. Archived from the original on 26 October 2020. Retrieved 20 August 2020.
  7. ^ a b c d "Viadur- leuprolide acetate". DailyMed. Archived from the original on 27 May 2021. Retrieved 26 May 2021.
  8. ^ a b c d "Lupron Depot- leuprolide acetate kit". DailyMed. Archived from the original on 27 May 2021. Retrieved 27 May 2021.
  9. ^ a b "Camcevi EPAR". European Medicines Agency (EMA). 22 March 2022. Retrieved 21 June 2022.
  10. ^ a b c d e f g h i "Leuprolide Acetate". The American Society of Health-System Pharmacists. Archived from the original on 23 December 2016. Retrieved 8 December 2016.
  11. ^
    hdl:10665/325771
    . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  12. ISBN 978-3-527-60749-5. Archived
    from the original on 20 June 2021. Retrieved 19 September 2020.
  13. PMID 16176939
    .
  14. PMID 16449344
    .
  15. ^ "Lupron, used to halt puberty in children, may cause lasting health problems". STAT. 2 February 2017. Archived from the original on 7 December 2020. Retrieved 7 December 2020.
  16. PMID 19281314
    .
  17. ISBN 978-1-60623-115-9. Archived
    from the original on 2 July 2014. Retrieved 24 March 2012.
  18. S2CID 22526704
    .
  19. S2CID 222832326
    .
  20. S2CID 30150360
    .
  21. ^ "Hormone Therapy in Gender Dysphoria" (PDF). NHS Guideline. Archived from the original (PDF) on 5 June 2022. Retrieved 22 April 2022. Table 1
  22. ^ "Hormone Therapy in Gender Dysphoria" (PDF). NHS Guideline. Table 1
  23. PMID 15568711
    .
  24. S2CID 19365144
    .
  25. S2CID 24065433
    .
  26. PMID 16986003
    .
  27. ^ "Common Side Effects of Lupron (Leuprolide Acetate Injection) Drug Center". Archived from the original on 29 July 2015. Retrieved 26 July 2015.[full citation needed]
  28. PMID 16321765
    .
  29. ^ Jewett C (2 February 2017). "Women Fear Drug They Used To Halt Puberty Led To Health Problems". Kaiser Health Network. Retrieved 17 November 2022.
  30. ISBN 978-3-8047-1763-3
    .
  31. PMID 8917899. Archived
    from the original on 8 December 2015.
  32. S2CID 30843402
    .
  33. ISBN 978-1-60913-704-5. Archived
    from the original on 13 June 2021. Retrieved 29 August 2018.
  34. ISBN 978-0-323-29354-9. Archived
    from the original on 11 August 2021. Retrieved 29 August 2018.
  35. ISBN 978-1-935281-91-7. Archived
    from the original on 13 June 2021. Retrieved 29 August 2018.
  36. ^ "Leuprolide Long-acting – Medical Mutual" (PDF). 21 May 2020. Archived from the original on 11 August 2021. Retrieved 11 August 2021.
  37. ^ "Lupron Depot- leuprolide acetate kit". DailyMed. Archived from the original on 27 May 2021. Retrieved 27 May 2021.
  38. ^ "Lupron Depot- leuprolide acetate kit". DailyMed. Archived from the original on 27 May 2021. Retrieved 27 May 2021.
  39. ^ "Lupron Depot-Ped- leuprolide acetate kit". DailyMed. Archived from the original on 27 May 2021. Retrieved 27 May 2021.
  40. ^ Ibrahim A (25 May 2021). "Camcevi (leuprolide) NDA Approval" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 27 May 2021. Retrieved 27 May 2021.
  41. ^ "Lupaneta Pack- leuprolide acetate and norethindrone acetate kit". DailyMed. Archived from the original on 27 May 2021. Retrieved 27 May 2021.
  42. ^ "Lupaneta Pack- leuprolide acetate and norethindrone acetate kit". DailyMed. Archived from the original on 27 May 2021. Retrieved 27 May 2021.
  43. ^
    ISBN 978-1-4666-4563-9. Archived
    from the original on 13 June 2021. Retrieved 27 August 2018.
  44. ^
    ISBN 978-1-84376-566-0. Archived
    from the original on 13 June 2021. Retrieved 27 August 2018.
  45. ^ Esber EC (21 May 1985). "Lupron (Leuprolide acetate) NDA approval" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 10 April 2021. Retrieved 27 May 2021.
  46. ^ Ernst D (4 May 2020). "Fensolvi Approved for Central Precocious Puberty". MPR. Archived from the original on 5 November 2020. Retrieved 19 August 2020.
  47. ^ a b "Camcevi: Pending EC decision". European Medicines Agency (EMA). 24 March 2022. Archived from the original on 29 March 2022. Retrieved 28 March 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  48. ^ "Camcevi Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  49. ^
    ISBN 978-1-4757-2085-3. Archived
    from the original on 13 June 2021. Retrieved 25 February 2018.
  50. ^
    ISBN 978-3-88763-075-1. Archived
    from the original on 13 June 2021. Retrieved 25 February 2018.
  51. ^
    ISBN 978-9-401144-39-1. Archived
    from the original on 13 June 2021. Retrieved 25 February 2018.
  52. ^ a b "Leuprorelin". Drugs.com. Archived from the original on 25 February 2018. Retrieved 25 February 2018.
  53. PMID 11597964
    .
  54. ^
    ISSN 0362-4331
    . Retrieved 24 January 2022.
  55. ^ a b "#513: 10-03-01 TAP PHARMACEUTICAL PRODUCTS INC. AND SEVEN OTHERS CHARGED WITH HEALTH CARE CRIMES COMPANY AGREES TO PAY $875 MILLION TO SETTLE CHARGES". www.justice.gov. Retrieved 24 January 2022.
  56. ^ "What You Should Know About Lupron Class Action Lawsuit". Law Answer. 8 May 2021. Retrieved 28 February 2022.
  57. ^ "Abbott, AbbVie Defeat Long-Running Lupron Bone, Joint Suit (1)". news.bloomberglaw.com. Retrieved 28 February 2022.
  58. ^ "More women come forward with complaints about Lupron side effects". KTNV. 12 February 2019. Retrieved 28 February 2022.
  59. ^ Center for Drug Evaluation and Research (30 September 2019). "January - March 2017 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)". FDA.
  60. S2CID 5546284
    .
  61. ^ a b c d "Leuprorelin oral - Enteris BioPharma". Adis Insight. Springer Nature Switzerland AG. Archived from the original on 4 November 2017. Retrieved 16 July 2018.
  62. PMID 19180717
    .
  63. PMID 20446034
    .
  64. ^ "Treatment of Chronic Egg Laying". Yarmouth Veterinary Center. Archived from the original on 24 November 2020. Retrieved 29 December 2020.

Further reading

  • Shajnfeld A, Krueger RB (July 2006). "Reforming (Purportedly) Non-Punitive Responses to Sexual Offending". Developments in Mental Health Law. 25: 81.
    SSRN 1077282
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Leuprorelin&oldid=1232520127"